These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 2440994

  • 1. Alzheimer-like neurotransmitter deficits in adult Down's syndrome brain tissue.
    Godridge H, Reynolds GP, Czudek C, Calcutt NA, Benton M.
    J Neurol Neurosurg Psychiatry; 1987 Jun; 50(6):775-8. PubMed ID: 2440994
    [Abstract] [Full Text] [Related]

  • 2. Catecholamines and cholinergic enzymes in pre-senile and senile Alzheimer-type dementia and Down's syndrome.
    Yates CM, Simpson J, Gordon A, Maloney AF, Allison Y, Ritchie IM, Urquhart A.
    Brain Res; 1983 Nov 28; 280(1):119-26. PubMed ID: 6228286
    [Abstract] [Full Text] [Related]

  • 3. Regional brain 5-hydroxytryptamine levels are reduced in senile Down's syndrome as in Alzheimer's disease.
    Yates CM, Simpson J, Gordon A.
    Neurosci Lett; 1986 Apr 11; 65(2):189-92. PubMed ID: 2940479
    [Abstract] [Full Text] [Related]

  • 4. Biochemical changes in Alzheimer's disease-senile dementia: neurotransmitters in senile dementia of the Alzheimer's type.
    Davies P.
    Res Publ Assoc Res Nerv Ment Dis; 1979 Apr 11; 57():153-66. PubMed ID: 33427
    [No Abstract] [Full Text] [Related]

  • 5. Neurotransmitters in the brains of patients with dementia disorders.
    Gottfries CG.
    Dan Med Bull; 1985 Feb 11; 32 Suppl 1():44-8. PubMed ID: 2580668
    [No Abstract] [Full Text] [Related]

  • 6. Cerebrospinal fluid monoaminergic metabolites are elevated in adults with Down's syndrome.
    Kay AD, Schapiro MB, Riker AK, Haxby JV, Rapoport SI, Cutler NR.
    Ann Neurol; 1987 Apr 11; 21(4):408-11. PubMed ID: 2437853
    [Abstract] [Full Text] [Related]

  • 7. Acetylcholine and aromatic amine systems in postmortem brain of an infant with Down's syndrome.
    McGeer EG, Norman M, Boyes B, O'Kusky J, Suzuki J, McGeer PL.
    Exp Neurol; 1985 Mar 11; 87(3):557-70. PubMed ID: 2857653
    [Abstract] [Full Text] [Related]

  • 8. Life-long overexpression of S100beta in Down's syndrome: implications for Alzheimer pathogenesis.
    Griffin WS, Sheng JG, McKenzie JE, Royston MC, Gentleman SM, Brumback RA, Cork LC, Del Bigio MR, Roberts GW, Mrak RE.
    Neurobiol Aging; 1998 Mar 11; 19(5):401-5. PubMed ID: 9880042
    [Abstract] [Full Text] [Related]

  • 9. Loss of neurones from cortical and subcortical areas in Down's syndrome patients at middle age. Quantitative comparisons with younger Down's patients and patients with Alzheimer's disease.
    Mann DM, Yates PO, Marcyniuk B, Ravindra CR.
    J Neurol Sci; 1987 Aug 11; 80(1):79-89. PubMed ID: 2956368
    [Abstract] [Full Text] [Related]

  • 10. Neurotransmitter deficits in Alzheimer's disease and in other dementing disorders.
    Mann DM, Yates PO.
    Hum Neurobiol; 1986 Aug 11; 5(3):147-58. PubMed ID: 2876973
    [Abstract] [Full Text] [Related]

  • 11. Small cerebral hemispheres in adults with Down's syndrome: contributions of developmental arrest and lesions of Alzheimer's disease.
    de la Monte SM, Hedley-Whyte ET.
    J Neuropathol Exp Neurol; 1990 Sep 11; 49(5):509-20. PubMed ID: 2148772
    [Abstract] [Full Text] [Related]

  • 12. [Ageing and neurotransmitters].
    Nakamura S, Miyata S.
    Nihon Naika Gakkai Zasshi; 1985 Oct 11; 74(10):1348-52. PubMed ID: 2869092
    [No Abstract] [Full Text] [Related]

  • 13. Neurotensin immunoreactivity in post-mortem brain is increased in Down's syndrome but not in Alzheimer-type dementia.
    Yates CM, Fink G, Bennie JG, Gordon A, Simpson J, Eskay RL.
    J Neurol Sci; 1985 Mar 11; 67(3):327-35. PubMed ID: 3157784
    [Abstract] [Full Text] [Related]

  • 14. High brain myo-inositol levels in the predementia phase of Alzheimer's disease in adults with Down's syndrome: a 1H MRS study.
    Huang W, Alexander GE, Daly EM, Shetty HU, Krasuski JS, Rapoport SI, Schapiro MB.
    Am J Psychiatry; 1999 Dec 11; 156(12):1879-86. PubMed ID: 10588400
    [Abstract] [Full Text] [Related]

  • 15. Neurotransmitter changes in early- and late-onset Alzheimer-type dementia.
    Arai H, Ichimiya Y, Kosaka K, Moroji T, Iizuka R.
    Prog Neuropsychopharmacol Biol Psychiatry; 1992 Dec 11; 16(6):883-90. PubMed ID: 1381103
    [Abstract] [Full Text] [Related]

  • 16. Monoaminergic and cholinergic synaptic markers in the nucleus basalis of Meynert (nbM): normal age-related changes and the effect of heart disease and Alzheimer's disease.
    Sparks DL, Hunsaker JC, Slevin JT, DeKosky ST, Kryscio RJ, Markesbery WR.
    Ann Neurol; 1992 Jun 11; 31(6):611-20. PubMed ID: 1355334
    [Abstract] [Full Text] [Related]

  • 17. Pathological evidence for neurotransmitter deficits in Down's syndrome of middle age.
    Mann DM, Yates PO, Marcyniuk B, Ravindra CR.
    J Ment Defic Res; 1985 Jun 11; 29 ( Pt 2)():125-35. PubMed ID: 2411933
    [Abstract] [Full Text] [Related]

  • 18. Alzheimer-like brain monoamine deficits in adults with Down's syndrome.
    Reynolds GP, Godridge H.
    Lancet; 1985 Dec 14; 2(8468):1368-9. PubMed ID: 2866421
    [No Abstract] [Full Text] [Related]

  • 19. Alzheimer's disease and Down's syndrome.
    Price DL, Whitehouse PJ, Struble RG, Coyle JT, Clark AW, Delong MR, Cork LC, Hedreen JC.
    Ann N Y Acad Sci; 1982 Dec 14; 396():145-64. PubMed ID: 6217772
    [No Abstract] [Full Text] [Related]

  • 20. The development of the pathologic changes of Alzheimer's disease and senile dementia in patients with Down's syndrome.
    Burger PC, Vogel FS.
    Am J Pathol; 1973 Nov 14; 73(2):457-76. PubMed ID: 4271339
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.